The Melanoma Letter Spring 2017, Vol. 35, No. 1

In this issue of The Melanoma Letter, Drs. Jedd Wolchok and James Larkin report on the exciting synergistic benefits of nivolumab-ipilimumab, the only FDA-approved combination checkpoint blockade therapy to date. While this drug combination has produced spectacular results, the authors also point out the serious side effects that can come with it, rarely life-threatening but sometimes requiring lifelong management. They also acknowledge that 30 or 40 percent survival is still far from ideal, and that concerted research must continue to find alternate and complementary ways to harness the immune system more perfectly, as well as markers that can tell us more precisely which individual and combination therapies will work best for which patients.